SteadyMed Announces FDA Agreed Pathway to Trevyent NDA Resubmission Post author:Sam Post published:December 7, 2017 Post category:BioPharma No clinical trials are required for the NDA resubmission. Source: BioSpace You Might Also Like Japan's PeptiDream Bags $1.11B+ R&D Pact With Bayer November 19, 2017 Bioverativ To Report Second Quarter 2017 Financial Results On August 2, 2017 July 6, 2017 5 Top Biotech Stocks That Look Vulnerable in 2018 January 8, 2018
